Anaconda Biomed raises $56m for catheter portfolio’s advance

The funds will support Anaconda's clinical development aims and the completion of its pivotal IDE study. The funds will support Anaconda's clinical development aims and the completion of its pivotal IDE study. According to GlobalData analysis, the stroke treatment market is shifting in favour of advanced aspiration technologies. Credit: Anusorn Nakdee/Shutterstock.com Anaconda Biomed has raised $56m to advance the clinical development of its mechanical thrombectomy catheter portfolio and complete the pivotal investigational device exemption (IDE) study for its ANA funnel catheter. The Spain-headquartered company’s financing round was led by Omega Funds and was joined by new investor FOCO, a co-investment…

Source: Medical Device Network